Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

NCT05078866 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

NIH

Sponsor class

Conditions

Colorectal Carcinoma
Lynch Syndrome

Interventions

BIOLOGICAL: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
PROCEDURE: Biospecimen Collection
PROCEDURE: Endoscopic Biopsy
BIOLOGICAL: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)